ArticleGenome biology2025
Rational design of promoter editing confers multipathogen resistance in rice.
Article in Genome biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Metabolite-mediated plant immunity: From traditional defenders to artificial elicitors.Journal of integrative plant biology · 2026Review
- A leucine-rich-repeat receptor-like kinase SERL1 phosphorylates and stabilizes OsALDH2B1 to promote alkaline tolerance and grain size in rice.Journal of integrative plant biology · 2026Article
- Transcending the jasmonate-mediated growth-defense trade-off: Pathways to unlocking plant potential.Plant communications · 2026Review
- Rice Annotation Project Database (RAP-DB): Literature-Curated Gene Annotation and Integrated Omics Resources for Rice Functional Genomics and Molecular Breeding.Rice (New York, N.Y.) · 2026Article
- Exploiting plant immune "switches" for resistance engineering.Stress biology · 2026Review
- Multiplex Gene Editing Creates Triple-Resistant Rice Against Both Insect Herbivores and Pathogens.Plants (Basel, Switzerland) · 2026Article
- Rational design of promoter editing confers multipathogen resistance in rice.Genome biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
backgroundFine-tuned gene expression rather than alterations in the protein-coding region of a gene is responsible for the optimal performance conferred by many elite alleles in crops. Lesion mimic mutants (LMMs), a type of plant mutants with hyperactivated immune responses, often show enhanced resistance but with yield penalties. To fine-tune the expression level of LMM genes using promoter editing is of considerable interest in crop disease control.
resultsHere we demonstrate the power of predictive promoter editing in optimizing expression of the rice LMM gene RBL1, encoding a CDP-DAG synthase in phospholipid metabolism, by breaking immunity-growth trade-offs. Through bioinformatic analyses of open chromatin accessibility, we identify key cis-regulatory regions in the RBL1 promoter. Guided by these predictions, we efficiently assess the regulatory role of different cis-regulatory regions in the rice protoplast system and then generate multiple promoter-edited rice lines with varied RBL1 expression levels. Notably, Pro1, an edited line with a 71.0% reduction in gene expression and altered levels of multiple phospholipids, shows broad-spectrum resistance to rice blast without compromising yield in field trials. Similarly, we generate a phenotype-copied PRO1 allele for enhanced disease resistance in another rice cultivar.
conclusionsOur study has generated an edited promoter of RBL1 that confers multipathogen resistance with no yield penalty. Our study demonstrates a framework for predictable promoter engineering in balancing agronomic traits, especially through optimizing LMMs for crop improvement.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.